Preparation of Protein Samples for SDS-Polyacrylamide Gel Electrophoresis: Procedures and Tips Anthony C
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Green Fluorescent Protein (GFP) Purification Student Manual
Green Fluorescent Protein (GFP) Purification Student Manual "Bioengineered DNA was, weight for weight, the most valuable material in the world. A single microscopic bacterium, too small to see with the human eye, but containing the gene for a heart attack enzyme, streptokinase, or for "ice-minus" which prevented frost damage to crops, might be worth 5 billion dollars to the right buyer." Michael Crichton - Jurassic Park Contents Lesson 1 Genetic Transformation Review—Finding the Green Fluorescent Molecule Lesson 2 Inoculation—Growing a Cell Culture Lesson 3 Purification Phase 1—Bacterial Concentration and Lysis Lesson 4 Purification Phase 2—Removing Bacterial Debris Lesson 5 Purification Phase 3—Protein Chromatography 26 Lesson 1 Finding the Green Fluorescent Molecule Genetic Transformation Review In Bio-Rad Kit 1, you performed a genetic transformation of E. coli bacterial cells. The results of this procedure were colonies of cells that fluoresced when exposed to ultraviolet light. This is not a normal phenotype (characteristic) for E.coli. You were then asked to fig- ure out a way to determine which molecule was becoming fluorescent under UV light. After determining that the pGLO plasmid DNA was not responsible for the fluorescence under the UV light, you concluded that it was not the plasmid DNA that was fluorescing in response to the ultraviolet light within the cells. This then led to the next hypothesis that if it is not the DNA fluorescing when exposed to the UV light, then it must be a protein that the new DNA pro- duces within the cells. 1. Proteins. a. What is a protein? b. -
Protocols and Tips in Protein Purification
Department of Molecular Biology & Biotechnology Protocols and tips in protein purification or How to purify protein in one day Second edition 2018 2 Contents I. Introduction 7 II. General sequence of protein purification procedures 9 Preparation of equipment and reagents 9 Preparation and use of stock solutions 10 Chromatography system 11 Preparation of chromatographic columns 13 Preparation of crude extract (cell free extract or soluble proteins fraction) 17 Pre chromatographic steps 18 Chromatographic steps 18 Sequence of operations during IEC and HIC 18 Ion exchange chromatography (IEC) 19 Hydrophobic interaction chromatography (HIC) 21 Gel filtration (SEC) 22 Affinity chromatography 24 Purification of His-tagged proteins 25 Purification of GST-tagged proteins 26 Purification of MBP-tagged proteins 26 Low affinity chromatography 26 III. “Common sense” strategy in protein purification 27 General principles and tips in “common sense” strategy 27 Algorithm for development of purification protocol for soluble over expressed protein 29 Brief scheme of purification of soluble protein 36 Timing for refined purification protocol of soluble over -expressed protein 37 DNA-binding proteins 38 IV. Protocols 41 1. Preparation of the stock solutions 41 2. Quick and effective cell disruption and preparation of the cell free extract 42 3. Protamin sulphate (PS) treatment 43 4. Analytical ammonium sulphate cut (AM cut) 43 5. Preparative ammonium sulphate cut 43 6. Precipitation of proteins by ammonium sulphate 44 7. Recovery of protein from the ammonium sulphate precipitate 44 8. Analysis of solubility of expression 45 9. Analysis of expression for low expressed His tagged protein 46 10. Bio-Rad protein assay Sveta’s easy protocol 47 11. -
Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications, -
Optical Properties and Denaturation by Guanidinium Chloride and Urea
Biochem. J. (1977) 161, 321-331 321 Printed in Great Britain Optical Properties and Denaturation by Guanidinium Chloride and Urea of the Adenosine Triphosphatase of Micrococcus lysodeikticus A COMPARISON OF FOUR MOLECULAR FORMS OF THE ENZYME By MANUEL NIETO and JUAN A. AYALA Seccion de Bioquimica de Membranas, Centro de Investigaciones Biol6gicas, Veldzquez 144, Madrid-6, Spain (Received 7 July 1976) 1. The fluorescence and circular dichroism offour homogeneous preparations of ATPase (adenosine triphosphatase) fromMicrococcus lysodeikticus differing in molecular structure and enzymic properties were examined at pH 7.5 and 25°C. Emission was maximum at 325 and 335nm and the relative intensities at these wavelengths may be used to characterize the different ATPase preparations. The circular-dichroism spectra exhibited negative extrema at 208 and 220nm, and the relative value of the molar ellipticity at these wave- lengths was also different for each molecular form ofthe enzyme. 2. The four preparations undergo two consecutive major unfolding transitions in guanidinium chloride (midpoints at 0.94 and 1.5 M denaturant), with concomitant destruction ofthe quaternary structure of the protein. A comparatively minor alteration in the ATPase structure also occurred in 0.05-0.2M-guanidine and led to complete inactivation ofthe enzyme. The inactivation and the first unfolding transition were reversible by dilution of the denaturant; the transition with midpoint at 1.5M-guanidine was irreversible. 3. Similar results were obtained in urea, except that the successive transitions had midpoints at concentrations of denaturant of 0.4, 2.0 and 4.5M. Low concentrations of urea caused a noticeable activation of the enzyme activity and alterations of the electrophoretic mobility of the ATPase. -
Challenges Associated with the Development and Validation of Flow Cytometry Assays
Challenges associated with the development and validation of flow cytometry assays Carolyne Dumont, Eliane Moisan, Martin Poirier, Marie-Hélène Côté, and Marie-Soleil Piché 1 INTRODUCTION 2 Case Study 1 3 Case Study 2 Development of a PD marker by flow cytometry to assess the efficacy of Development of a flow cytometry assay for the measurement of basophil Flow cytometry is a technology allowing multi-parametric analysis of thousands of particles per second and helps to a chemokine neutralizing antibody activation in the context of a Phase III clinical study adequately identify or functionally characterize complex cell populations of interest. It is often used in basic research, Assay Design: The assay was required for the evaluation of pharmacodynamics (inhibition an agonist’s granulocytes activation activity) in Assay Design: Human whole blood samples were spiked with the different controls (or compounds in the clinical study) and further discovery, preclinical and clinical trials. With the increasing proportion of biologics in the pipeline, flow cytometry has proven preclinical studies. Non-Human Primate (NHP) or rat blood from treated animals was incubated at 3 conditions and granulocyte activation stained with an anti-CCR3 and anti-CD63 antibody. The validations stimulation conditions tested included a negative control (PBS) and itself to be an indispensable tool to assess safety, receptor occupancy (RO) or pharmacodynamics (PD). was measured as CD11b expression by flow cytometry (MFI). The conditions tested included a negative control (PBS), a positive control two positive controls (anti-FcεRI and fMLP). Basophils were identified as CCR3+ and upon activation, CD63 became externalized and (fMLP) and the test condition (agonist). -
Western Blotting Guidebook
Western Blotting Guidebook Substrate Substrate Secondary Secondary Antibody Antibody Primary Primary Antibody Antibody Protein A Protein B 1 About Azure Biosystems At Azure Biosystems, we develop easy-to-use, high-performance imaging systems and high-quality reagents for life science research. By bringing a fresh approach to instrument design, technology, and user interface, we move past incremental improvements and go straight to innovations that substantially advance what a scientist can do. And in focusing on getting the highest quality data from these instruments—low backgrounds, sensitive detection, robust quantitation—we’ve created a line of reagents that consistently delivers reproducible results and streamlines workflows. Providing scientists around the globe with high-caliber products for life science research, Azure Biosystems’ innovations open the door to boundless scientific insights. Learn more at azurebiosystems.com. cSeries Imagers Sapphire Ao Absorbance Reagents & Biomolecular Imager Microplate Reader Blotting Accessories Corporate Headquarters 6747 Sierra Court Phone: (925) 307-7127 Please send purchase orders to: Suite A-B (9am–4pm Pacific time) [email protected] Dublin, CA 94568 To dial from outside of the US: For product inquiries, please email USA +1 925 307 7127 [email protected] FAX: (925) 905-1816 www.azurebiosystems.com • [email protected] Copyright © 2018 Azure Biosystems. All rights reserved. The Azure Biosystems logo, Azure Biosystems™, cSeries™, Sapphire™ and Radiance™ are trademarks of Azure Biosystems, Inc. More information about Azure Biosystems intellectual property assets, including patents, trademarks and copyrights, is available at www.azurebiosystems.com or by contacting us by phone or email. All other trademarks are property of their respective owners. -
DTT (Dithiothreitol)
FT-054721(284251) DTT (DithioThreitol) Product Information Catalog #: 054721, 5g 054722, 25g Name: DTT (DithioThreitol), Biotech grade CAS: 3483-12-3 Molecular Weight : MW: 154.25 Typical values: Purity: >99.4% Abs@283nm (0.1M, water):<0.05 Loss on drying: <0.5% other names: mp: 39-43°C (2S,3S)-1,4-Bis-sulfanylbutane-2,3-diol Oxidized DTT: <0.5% Threo-1,4-dimercaptobutane-2,3-diol Protease: none DL-Threo-1,4-dimercapto-2,3-butanediol DNase: none 1,4-Dithio-DL-threitol, ±-Threo-1,4-dimercapto- RNase: none 2,3-butanediol Storage: -20°C (or 4°C short term). (M) Cleland's reagent, Reductacryl Protect from moisture. Keep dry Harmful / Irritant; R: 36/37/38; S: 26-36 Cleland’s Reagent, or Dithiothreitol (DTT), is a water-soluble reducing reagent used for various applications in biotechnology, biology and biochemistry : - reduces quantitatively disulfides, generating sulfhydryls (used typically at 1-10mM for protein SS reduction) - reduction of proteins before SDS-PAGE analysis, studies of protein structure and function (Kaji 1993) - keep sulfhydryl groups of biomolecules in the reduced state - protects biomolecules in various applications (enzymes or receptors, living cells under ionizing radiations) - prevents the fading of fluorescence such as FITC labeled conjugates (Picciolo 1984) Technical and Scientific Information Dithiothreitol (DTT), also known as Cleland's reagent, is a small-molecule redox reagent . Its oxidized form is a disulfide-bonded 6-membered ring. DTT has an epimeric ('sister') compound, dithioerythritol (DTE, #123378). DTT is highly soluble in water (clear solution, OD<0.05 at 0.02M), but also in ethanol, chloroform, ether and ethyl acetate. -
Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes
Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes Paula Denney Eason, Renée C. Benson, Jenny T. Ly, Rachel A. Saxer, James L. Wilbur, George B. Sigal, Eli N. Glezer, Hans A. Biebuyck, Jacob N. Wohlstadter, and Robert M. Umek TM TM A division of Meso Scale Diagnostics,TM LLC. Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes Abstract This poster presents a robust, receptor-ligand binding assay based upon a novel assay platform developed by Meso Scale DiscoveryTM (MSDTM). MSD’s platform combines array technologies and electrochemiluminescence detection to achieve ultra-fast, highly sensitive assays in a homogeneous format. Cellular membranes containing the EGF receptor were passively adsorbed to MSD proprietary coated electrodes embedded in multi-well plates. Binding of EGF to the EGF receptor was detected by inducing and measuring electrochemi- luminescence from a labeled EGF ligand. Approximately 1000 cell equivalents per well yielded a signal to background ratio of 20. The observed KD agrees with that reported in the literature and demonstrates that immobilization of the membranes and modification of the ligand do not alter the binding affinity. Binding specificity was confirmed with two inhibitors. The assay can be readily adapted to facilitate analysis of a broad array of receptor-ligand interactions. TM TM A division of Meso Scale Diagnostics,TM LLC. Simple, Rapid Ligand-Binding Assay Using Immobilized Cellular Membranes TM Multi-Array TechnologyTM Multi-Array Technology Unified technology platform with instruments, plates and reagents for drug discovery for drug discovery. Combines the power of microarrays with the sensitivity of electrochemiluminescence Combines the power of microarrays with the sensitivity of electrochemiluminescence.96-, 384- and 1536 microplate formats 96-,Multi-Spot 384- TMand plates 1536 with microplate high density formats. -
Irect Measurement of the Equilibrium Between Glutathione and Dithiothreitol by High Performant;E Liquid Chromatography
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 291. number 2. 296-298 FEES 10260 October 199 I 0 1991 Federation of European Biochemical Societies 00145793/911$3 50 ADONIS 0014579391009708 irect measurement of the equilibrium between glutathione and dithiothreitol by high performant;e liquid chromatography Mei-Hmg Chau and Jeffrey W. Nelson Deprtnlent of Btochemrsrry, Loutsrana Stare Unwersr~y, &ton. Rouge, LA 90803-1806, USA Received 17 Yuly 1991 The equthbrmm constant between reduced glutathlone (GSH), oxldlzed glutathlone (GSSG), reduced chthlothreltol (DTT:!), and oxidized dlthrothreltol (DTT~) has been directly measured by Hugh performance hqutd chromatography analysis of cqulhbrmm mixtures The equihbnum constdnt at 2YC for the reactlon GSSG + DTT:! + 2GSH -t De vanes from approximately 200 M, below pH 8, to approxnnately 2800 M. above pH 11 The observed pH dependence IS generally consistent with pubhshed values of acid dlssoclatIon constants of these thlols Glutathlonc. Dlthlothrenol, Thiol reagent, Dlsulfide exchange 1. INTRODUCTION We are currently carrymg out equihbnum studies of dlsulfide exchange of a protem usmg both dlthiothreitol Dlthiothreltol and glutathione are common reagents and glutathlone Surprismgly, the equihbrmm constant for ths study of disulfide exchange reactions of protein between dlthlothreltol and glutathlone obtamed mdl- &sulfides [l-9] The stabtlity of a dlsulfide bond m a rectly m our studies, approximately 120 M at pH 7 0 protein can be represented by the equihbrium constant (unpubhshed data), was found to be different from pre- of the thlol-dlsulfide exchange between that protem dl- vlously reported values. -
Essential Role of Coenzyme a in Pyruvate Dehydrogenase Kinase Activity
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 148, number 2 FEBSLETTERS November1982 Essential role of coenzyme A in pyruvate dehydrogenase kinase activity E.A. Siess and O.H. Wieland Forschergruppe Diabetes and Institut fiir Klinische Chemie, Sttidtisches Krankenhaus Miinchen-Schwabing, Kd;lner Platz 1, D-8000 Miinchen 40, FRG Received 16 September 1982 The rate of phosphorylation and concomitant inactivation of purified pig heart muscle pyruvate de- hydrogenase complex by intrinsic kinase (EC 2.7.1.99) is markedly accelerated by the addition of co- enzyme A to the incubation medium, showing a half-maximum effect at 1.8 PM. The pantetheine moiety is the effective part of the coenzyme A molecule. The free thiol group is prerequisite for the stimulatory action, acetyl-CoA, benzoyl-CoA or CoAS-SCoA being ineffectual. The thiol’s specificity is evidenced by showing that dithiothreitol, 2-mercaptoethanol or glutathione up to 5 mM failed to replace coenzyme A. The possibility is considered that coenzyme A might act as a physiological modifier of pyruvate dehydrogenase kinase activity. Pyruvate dehydrogenase kinase Phosphorylation Coenzyme A Heart muscle 1. INTRODUCTION together with 50 ~1 0.1 M Na2CO3, 200 ~1 30 mM Tris-HCl buffer (pH 8.6) and 20 ~132 PM CuSO4 Recent work on highly purified pyruvate de- at 25°C. After 2 h, >90% of the initially titratable hydrogenase complex (PDH) from bovine kidney thiol content [4] had disappeared. [Y-~~P]ATP was suggests that protein thiol-disulfide exchange purchased from the Radiochemical Centre is involved in the regulation of PDH kinase (Amersham). -
The Art of Protein Purification
1 The Art of Protein Purification William Ward Rutgers University, New Brunswick NJ, USA 1. Introduction Describing, in words, the details of protein purification to a relative novice in the field is not unlike explaining on paper the steps required to turn a set of colored oils into a beautiful pastoral scene on sheet of stretched canvas. Playing the oboe in a sophisticated metropolitan orchestra or performing a solo aria in a Gilbert & Sullivan operetta are accepted artistic endeavors that command great mastery of technique. Each of these art forms requires years of experience and endless experimentation and refinement of technique. Protein purification is no different. It is an art form. Like all other art forms, perfecting the art of protein purification requires a long apprenticeship. But, like all other art forms, protein purification is aesthetically rewarding to the practitioner. Every day brings new challenges, new insights, new hurdles, and new successes. Art is a process, not a destination. Protein purification fits the same definition. Perfecting the skills of protein purification can take many years of hands-on experience as well as periodic upgrading of those skills. Perhaps the most important part of protein purification is the set of pre-column steps that precede column chromatography. Pre- column steps are not covered as much in the protein purification literature as column chromatography, HPLC, and electrophoresis. So, I have chosen to focus much of my attention on the earlier stages of protein purification. More than column chromatography, pre-column steps are highly diverse and highly creative. Here the artistic aspects of protein purification are most apparent. -
DL-Dithiothreitol Solution (646563)
DL-Dithiothreitol Solution 1 M in H2O Catalog Number 646563 Store at Room Temperature CAS RN 3483-12-3 Precautions and Disclaimer Synonyms: Cleland's Reagent, DTT For R&D use only. Not for drug, household, or other Molecular Formula: C4H10O2S2 uses. Please consult the Safety Data Sheet for Molecular Weight: 154.3 information regarding hazards and safe handling practices. Product Description Dithiothreitol (DTT) is used in proteomics applications Preparation Instructions to maintain sulfhydryl (–SH) groups in the reduced state This product is supplied as a ready-to-use 1 M solution. and for quantitative reduction of disulfide (–S–S–) groups, as described by Cleland in his pioneering work Storage/Stability in the 1960's.1 By reducing the disulfide bonds in a The unopened product is stable for at least two years at protein sample, the protein can be more effectively room temperature. fragmented and analyzed. Procedure DTT is a commonly used reagent in buffers because of SDS-PAGE sample preparation with DTT its ability to reduce the oxidation state of a protein 1. Dilute the 1 M DTT Solution to 50 mM by adding sample, and thereby, preserve enzymatic activity.2 50 L of the 1 M DTT Solution to 950 L of DTT is oxidized to the cyclic disulfide during the ultrapure water. reduction of other disulfides in solution. Disulfide 2. Aliquots of the 50 mM can be added to the samples reduction is typically complete in minutes at pH 8. Its to a final concentration of 5 mM. usefulness stems from its water solubility, reduced 3.